ed ▁under ▁the ▁trade ▁names ▁A ry o Se ven ▁and ▁Nov o Se ven , ▁is ▁used ▁for ▁people ▁with ▁hem oph ilia ▁( with ▁F actor ▁VIII ▁or ▁IX ▁def ic iency ) ▁who ▁have ▁developed ▁ant ib od ies ▁against ▁replacement ▁co ag ulation ▁factor . ▁ ▁It ▁has ▁also ▁been ▁used ▁in ▁the ▁setting ▁of ▁un cont roll able ▁hem or rh age , ▁but ▁its ▁role ▁in ▁this ▁setting ▁is ▁controvers ial ▁with ▁ins u fficient ▁evidence ▁to ▁support ▁its ▁use ▁outside ▁of ▁clin ical ▁tri als . ▁The ▁first ▁report ▁of ▁its ▁use ▁in ▁hem or rh age ▁was ▁in ▁an ▁Isra eli ▁soldier ▁with ▁un cont roll able ▁ble eding ▁in ▁ 1 9 9 9 . ▁Ris ks ▁of ▁its ▁use ▁include ▁an ▁increase ▁in ▁ar ter ial ▁th rom b osis . ▁However , ▁animal ▁studies ▁have ▁not ▁shown ▁comp lications ▁as ▁seen ▁in ▁humans , ▁in ▁fact ▁same ▁of ▁the ▁studies ▁show ▁a ▁better ▁pro gn osis . ▁In ▁the ▁military ▁settings ▁it ▁is ▁used ▁as ▁an ▁off ▁label ▁inter vention ▁in ▁comp lications ▁related ▁to ▁dis sem in ated ▁int ra vas cular ▁co ag ulation ▁related ▁ha emor rh age ▁caused ▁by ▁pen etr ating ▁tra uma . ▁ ▁Re com bin ant ▁human ▁factor ▁VII ▁while ▁initially ▁looking ▁prom ising ▁in ▁int rac ere br al ▁hem or rh age ▁failed ▁to ▁show ▁benefit ▁following ▁further ▁study ▁and ▁this ▁is ▁no ▁longer ▁recommended . ▁ ▁Inter actions ▁▁ ▁F actor